Boehringer Ingelheim veteran executive Felix Gutsche shares the first impressions of the China market since he joined in January 2019; the strategic significance of the market as one of the top three affiliates for the Group globally across both Human Pharma and Animal Health business units; his mission to better integrate BI China into the global corporation while amplifying its voice; and his personal excitement at being part of the BI China journey.
Like many other Big Pharma companies, the global corporate organization has traditionally been more US- and Euro-centric but today, it needs to be more China-centric.
